enGene Holdings Inc. Warrants
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGen… Read more
enGene Holdings Inc. Warrants (ENGNW) - Total Liabilities
Latest total liabilities as of October 2025: $53.76 Million USD
Based on the latest financial reports, enGene Holdings Inc. Warrants (ENGNW) has total liabilities worth $53.76 Million USD as of October 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
enGene Holdings Inc. Warrants - Total Liabilities Trend (2021–2025)
This chart illustrates how enGene Holdings Inc. Warrants's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
enGene Holdings Inc. Warrants Competitors by Total Liabilities
The table below lists competitors of enGene Holdings Inc. Warrants ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CleanSpark, Inc. Warrant
NASDAQ:CLSKW
|
USA | $1.94 Billion |
|
Lux Industries Limited
NSE:LUXIND
|
India | ₹12.03 Billion |
|
Eltel AB
ST:ELTEL
|
Sweden | Skr484.91 Million |
|
Suwen Tekstil Sanayi Pazarlama AS
IS:SUWEN
|
Turkey | TL1.83 Billion |
|
Mogan Enerji Yatırım Holding As
IS:MOGAN
|
Turkey | TL53.95 Billion |
|
Abion Inc.
KQ:203400
|
Korea | ₩31.76 Billion |
|
Hope Education Group Co. Ltd
F:HE1
|
Germany | €12.42 Billion |
|
Sri Rejeki Isman(Sritex)PT
JK:SRIL
|
Indonesia | Rp1.61 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down enGene Holdings Inc. Warrants's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how enGene Holdings Inc. Warrants's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for enGene Holdings Inc. Warrants (2021–2025)
The table below shows the annual total liabilities of enGene Holdings Inc. Warrants from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-10-31 | $53.76 Million | +39.41% |
| 2024-10-31 | $38.56 Million | +166.43% |
| 2023-10-31 | $14.47 Million | +213.20% |
| 2022-10-31 | $4.62 Million | +13.96% |
| 2021-10-31 | $4.05 Million | -- |